674 related articles for article (PubMed ID: 34515227)
1. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
Taha HR; Keewan N; Slati F; Al-Sawalha NA
Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
4. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
5. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2020; 14(4):641-648. PubMed ID: 32428865
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
Moirangthem DS; Surbala L
Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
[TBL] [Abstract][Full Text] [Related]
10. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
11. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
12. Rapid review for the anti-coronavirus effect of remdesivir.
Li Z; Wang X; Cao D; Sun R; Li C; Li G
Drug Discov Ther; 2020; 14(2):73-76. PubMed ID: 32378648
[TBL] [Abstract][Full Text] [Related]
13. On the molecular structure of Remdesivir for the treatment of Covid-19.
Sheikholeslami SM; Jahanbani A; Shao Z
Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.
Lin HXJ; Cho S; Meyyur Aravamudan V; Sanda HY; Palraj R; Molton JS; Venkatachalam I
Infection; 2021 Jun; 49(3):401-410. PubMed ID: 33389708
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.
Chatterjee S
Drug Res (Stuttg); 2021 Mar; 71(3):138-148. PubMed ID: 33124007
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
Elife; 2021 Oct; 10():. PubMed ID: 34617885
[TBL] [Abstract][Full Text] [Related]
18. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
19. Use of remdesivir for patients with Covid-19: a review article.
Azevedo TCP; Azevedo PCP; Silveira Filho RN; Carvalho ARVS; Cezarotti Filho ML; Barbosa FT; Sousa-Rodrigues CF; Matos-Rocha TJ; Ramos FWDS
Rev Assoc Med Bras (1992); 2020 Jun; 66(6):838-841. PubMed ID: 32696862
[TBL] [Abstract][Full Text] [Related]
20. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]